OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Memorial Sloan Kettering Cancer Center · Beth Israel Deaconess Medical Center · +14 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
754
total citations
- FWCI
- 37.90
- Percentile
- 100%
- References
- 9
Citations per year
Authors
14- MEMark E. RobsonCorresponding
Memorial Sloan Kettering Cancer Center
- NTNadine Tung
Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center
- PCPierfranco Conté
Istituto Oncologico Veneto, Istituti di Ricovero e Cura a Carattere Scientifico
- SISeock‐Ah Im
Seoul National University Hospital
- ESElżbieta Senkus
Gdańsk Medical University
Topics & keywords
Topics
Keywords
- Medicine
- Olaparib
- Oncology
- BRCA mutation
- Tolerability
- Internal medicine
- Chemotherapy
- Germline
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.